Biocon
BIOCON
Performance
About Biocon
Biocon is a global biopharmaceutical company focused on innovation-led development and manufacturing of affordable biosimilars, generic formulations, and complex APIs. It operates across generics, biosimilars, novel biologics, branded formulations, and research services, with a multinational presence in the biopharmaceutical landscape. The company emphasizes access to medicines and a broad portfolio spanning diabetes, oncology, and immunology. Headquartered in India, Biocon positions itself as a leading player in the global biopharmaceutical industry.
Recent News
Syngene Hires Maninder Kapoor Puri as CHRO, Abhijit Zutshi as CCO
Pfeifer Retiring as AC Immune CEO — and More Biotech C-Suite Moves
Syngene Extends Major Research Collaboration with BMS
Shreehas Tambe Becomes First CEO of Newly Combined Biocon
Bernstein Forecasts India’s Biopharma Market to Hit $195 Bn by 2035 on Innovation Surge
Importing Rapamycin to Save Money (2)
Top Gainers & Losers on May 12: Kalyan Jewellers, Adani Power, Anant Raj, Tata Motors, BEML, UPL Among Top Losers
Generally Good Indian Pharma Companies
Biosimilar Ramp-Up to Drive Growth for Biocon in FY27
Generally Good Indian Pharma Companies
Health Canada Approves Biocon’s Two Denosumab Biosimilars
Biocon Gets Karthik SM as Head HR-India, Malaysia, Emerging Markets
From Trailblazer to Torchbearer at Biocon: Kiran Mazumdar-Shaw Picks Claire Mazumdar as Heir Apparent
Syngene International Names Abhijit Zutshi as Chief Commercial Officer to Drive Global CRO Growth